NCT02598661 · MORE INFO

Limitations, agreements, and source contact

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) · Source last updated 2026-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Consistent with Good Publication Practices and ICMJE guidelines, the sponsor shall have right to publish such primary (multicenter) data and information without approval from investigator. Investigator has right to publish study site-specific data after primary data published. If an investigator wishes to publish information from study, a copy of manuscript must be provided to sponsor for review at least 60 days before submission for publication or presentation.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: mds3001-info@Geron.com
organization: Geron Corp.
phone: 650-473-7700
title: Study Director

Complete source fields

certain Agreement

other Details: Consistent with Good Publication Practices and ICMJE guidelines, the sponsor shall have right to publish such primary (multicenter) data and information without approval from investigator. Investigator has right to publish study site-specific data after primary data published. If an investigator wishes to publish information from study, a copy of manuscript must be provided to sponsor for review at least 60 days before submission for publication or presentation.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: mds3001-info@Geron.com
organization: Geron Corp.
phone: 650-473-7700
title: Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice